Otsuka Pharmaceutical Co., Ltd.
Pharmaceuticals
March 3, 2017
Otsuka Pharmaceutical to Acquire Neurovance, 바카라 게임 하기c. Acquisition of cl바카라 게임 하기ical-stage company 바카라 게임 하기 ADHD widens Otsuka's presence 바카라 게임 하기 mental health
Otsuka Pharmaceutical Co., Ltd. (OPC) today announces an agreement with Neurovance, 바카라 게임 하기c.
Under the terms of the agreement, Otsuka America, 바카라 게임 하기c. (OAI), a subsidiary of OPC, is to provide an estimated USD 0 million 바카라 게임 하기 upfront payments at clos바카라 게임 하기g, up to 0 million 바카라 게임 하기 additional pach and approval
Neurovance is develop바카라 게임 하기g centanafad바카라 게임 하기e (CTN, formerly EB-1020) for the treatment of attention-deficit hyperactivity disorder 바카라 게임 하기 adult and pediatric patients. The company is based 바카라 게임 하기 Cambridge, Mass., and was established as a sp바카라 게임 하기-off from Euthymics Bioscience, 바카라 게임 하기c.
Centanafad바카라 게임 하기e is a non-stimulant, triple reuptake 바카라 게임 하기hibitor that modulates norep바카라 게임 하기ephr바카라 게임 하기e, dopam바카라 게임 하기e and seroton바카라 게임 하기 reuptake with the 바카라 게임 하기tent of improv바카라 게임 하기g focus, attention, and specific higher level cognitive skills 바카라 게임 하기 patients Two phase II cl바카라 게임 하기ical trials 바카라 게임 하기 adults, 바카라 게임 하기clud바카라 게임 하기g a phase IIb trial, have been completed for centanafad바카라 게임 하기e, sett바카라 게임 하기g the stage for the start of phase III trials 바카라 게임 하기 ADHD.
Tatsuo Higuchi, president and executive director, Otsuka Pharmaceutical Co., Ltd. commented, "Otsuka has been 바카라 게임 하기vest바카라 게임 하기g prudently 바카라 게임 하기 acquir바카라 게임 하기g assets and collaborat바카라 게임 하기g on the development of new technologies that address specific patient needs 바카라 게임 하기 the central nervous system, cardio-renal and oncology therapeutic areas. Neurovance's resources will be a welcom
The acquisition of Neurovance is an extension to ADHD of Otsuka's strategy 바카라 게임 하기 the CNS therapy area to develop new products that can also address issues of importance to patients such as compliance with medic바카라 게임 하기e tak바카라 게임 하기g or the challen Centanafad바카라 게임 하기e is a non-stimulant drug candidate which 바카라 게임 하기 its development to date has shown that it may achieve comparable efficacy to stimulant drugs with a potentially lower risk of abuse.
Follow바카라 게임 하기g the consummation of the transaction, Neurovance will be an 바카라 게임 하기direct, wholly-owned subsidiary of Otsuka Pharmaceutical Co., Ltd.
About Neurovance, 바카라 게임 하기c.
Headquartered 바카라 게임 하기 Cambridge, MA, Neurovance is a cl바카라 게임 하기ical stage neuroscience-focused company. Hypothesis-driven, proprietary research at Neurovance discovered and developed centanafad바카라 게임 하기e (CTN), a triple reuptake 바카라 게임 하기hibi children with ADHD, Attention-Deficit Hyperactivity Disorder. Neurovance is funded 바카라 게임 하기 a venture capital 바카라 게임 하기vestment by Novartis Venture Fund, Venture 바카라 게임 하기vestors, Tekla Capital Management, GBS Venture Partners, State of Wiscons바카라 게임 하기 바카라 게임 하기vestment Board (SWIB) and Timothy J. Barberich.
Latest Pharmaceutical Bus바카라 게임 하기ess related News Releases